Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study.
Kevin C OeffingerKayla L StrattonMelissa M HudsonWendy M LeisenringTara O HendersonRebecca M HowellSuzanne L WoldenLouis S ConstineLisa R DillerCharles A SklarPaul C NathanSharon M CastellinoDana BarneaSusan A SmithRaymond J HutchinsonGregory T ArmstrongLeslie L RobisonPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
This study demonstrates that risk-adapted therapy for pediatric HL has resulted in a significant reduction in serious long-term outcomes.